328 Stock Chart & Stats
€7.90
€0.05(0.83%)
At close: 4:00 PM EST
€7.90
€0.05(0.83%)
Day’s Range― - ―
52-Week Range€5.85 - €12.50
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€1.13B
Enterprise Value€980.06M
Total Cash (Recent Filing)€71.54M
Total Debt (Recent Filing)€87.53M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 06, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding92,609,510
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.88Price Target Upside176.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.46
Revenue Forecast (FY)€43.58M
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Improving Operating Cash FlowSustained ~94% gross margin indicates a high-value, scalable revenue mix with strong operating leverage potential. Operating cash flow turning positive (~$8M TTM) signals improving cash generation, reducing short‑term financing pressure and supporting continued investment in trials and commercialization over the next 2–6 months.
Multi-stage Royalty And Equity Financing Extends RunwayThe Oberland structure (initial funding plus milestone-linked tranches and capped royalties) plus a prior ~$93M public equity raise materially extends runway into 2H 2028. This reduces near-term liquidity risk, preserves equity (non-dilutive tranche), and provides optional capital tied to clinical/regulatory progress.
Durable Phase 1 AAV-hAQP1 Clinical DataThree-year durability and safety in Phase 1 for AAV-hAQP1 support this program's disease‑modifying potential and strengthen commercial case for a one‑time therapy in a concentrated patient population. Durable clinical effect improves payer and physician confidence and underpins longer-term revenue prospects if approved.
Bears Say
Negative Stockholders' EquityA negative equity position (~-$58M) signals past losses have eroded capital, constraining financial flexibility and increasing reliance on external funding. It raises creditor scrutiny, may limit borrowing capacity or favorable covenant terms, and elevates structural solvency risk over a multi‑quarter horizon.
Large Ongoing Net LossesA ~ $121M TTM net loss on ~$80M revenue shows the business has not yet scaled to cover fixed and development costs. Persistent operating and net deficits require sustained external funding or rapid revenue ramp to reach sustainable profitability, increasing execution risk over coming quarters.
Reliance On Milestone‑contingent Royalty FinancingSubstantial funding is structured as milestone‑contingent royalty financing, which preserves near‑term cash but commits future product revenues to royalties. Optional tranches depend on clinical/regulatory success, creating execution and cash‑availability risk and potentially reducing long‑term commercial margins.
Meiragtx Holdings News
328 FAQ
What was Meiragtx Holdings’s price range in the past 12 months?
Meiragtx Holdings lowest stock price was €5.85 and its highest was €12.50 in the past 12 months.
What is Meiragtx Holdings’s market cap?
Meiragtx Holdings’s market cap is €1.13B.
When is Meiragtx Holdings’s upcoming earnings report date?
Meiragtx Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Meiragtx Holdings’s earnings last quarter?
Meiragtx Holdings released its earnings results on May 14, 2026. The company reported -€0.499 earnings per share for the quarter, beating the consensus estimate of -€0.531 by €0.032.
Is Meiragtx Holdings overvalued?
According to Wall Street analysts Meiragtx Holdings’s price is currently Undervalued.
Does Meiragtx Holdings pay dividends?
Meiragtx Holdings does not currently pay dividends.
What is Meiragtx Holdings’s EPS estimate?
Meiragtx Holdings’s EPS estimate is -0.29.
How many shares outstanding does Meiragtx Holdings have?
Meiragtx Holdings has 92,609,510 shares outstanding.
What happened to Meiragtx Holdings’s price movement after its last earnings report?
Meiragtx Holdings reported an EPS of -€0.499 in its last earnings report, beating expectations of -€0.531. Following the earnings report the stock price went up 3.049%.
Which hedge fund is a major shareholder of Meiragtx Holdings?
Currently, no hedge funds are holding shares in DE:328
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€21.88 (176.93% Upside)
€21.88 (176.93% Upside)
Blogger Sentiment
Bullish
DE:328 Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.54%
12-Months-Change
Fundamentals
Return on Equity
474.91%
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Meiragtx Holdings
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
328 Stock 12 Month Forecast
Average Price Target
€21.88
▲(176.93% Upside)
Technical Analysis
Options Prices
Currently, No data available
---